Belite Bio (BLTE) Net Income (2020 - 2026)
Belite Bio (BLTE) posted quarterly Net Income of -$26.9 million for Q1 2026, down 88.68% year-over-year from -$238.0 million in Q1 2025, and up 99.89% quarter-over-quarter from -$25.3 billion in Q4 2025.
Analysis
Belite Bio (BLTE) Net Income (2020 - 2026) Analysis & Trends
Belite Bio's Net Income history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.
- In Q1 2026, Net Income fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 124.04% YoY), while the FY2025 annual figure was -$77.5 million, down 131.85% from the prior year.
- Net Income for Q1 2026 stood at -$26.9 million, up from -$25.3 billion in the prior quarter.
- The five-year high for Net Income was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
- The 5-year median for Net Income is -$6.9 billion (2023), against an average of -$7.4 billion.
- The sharpest annual moves came in 2024 and 2025: Net Income tumbled 144392.13% in 2024, then soared 99.82% in 2025.
- Belite Bio's Net Income stood at -$6.8 million in 2022, then dropped by 3.05% to -$7.0 million in 2023, then sank by 144392.13% to -$10.1 billion in 2024, then plunged by 150.73% to -$25.3 billion in 2025, then soared by 99.89% to -$26.9 million in 2026.
- Business Quant data shows BLTE's Net Income at -$26.9 million in Q1 2026, -$25.3 billion in Q4 2025, and -$21.7 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Belite Bio | 6.44 Bn | 6.44 Bn | - | -28.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.41 Mn |
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | 129.90 Mn |
| Sep 30, 2025 | -21.69 Mn |
| Jun 30, 2025 | -16.32 Mn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | 62.19 Mn |
| Sep 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -9.49 Mn |
| Mar 31, 2024 | -7.87 Mn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -68.12 |
| Mar 31, 2023 | -6.90 Mn |
| Dec 31, 2022 | -12.65 Mn |
| Jun 30, 2022 | -2.39 Mn |
| Dec 31, 2021 | -9.67 Mn |
| Dec 31, 2020 | -5.75 Mn |